UNSPSC 51422369: Prednisolone valerate acetate

This classification denotes a therapeutic glucocorticoid with the molecular formula C28H38O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2JB27QJW3D, chemically known as pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-17-((1-oxopentyl)oxy)-, (11.beta.)-, but more generally known as prednisolone valerate acetate, which bears US NIH Compound Identifier 135307.

European Medicines Agency schedules prednisolone valerate acetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10018MIG. Most nations, for tariff purposes, schedule prednisolone valerate acetate under HS 29372100. Prednisolone valerate acetate bears US NLM identifiers UMLS ID C1882445 and NCI Concept Code C66462. SMILES: CCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)COC(=O)C.

UNSPSC 51422369 Prednisolone valerate acetate is a Commodity code that in recent state and local procurement activity maps almost entirely to naloxone, drug deactivation systems, and broader pharmaceutical supply procurement rather than the specific corticosteroid named in the code. State and local issuing bodies soliciting under this code—including county health departments and state health and human services commissions—are buying pharmaceutical products and related community health supplies through competitive bidding and market-intelligence-gathering processes. The Seminole County, Florida procurement illustrates the scope: the county issued an IFB for annual purchases of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to a county community health building, requiring vendors to absorb shipping costs and maintain workers' compensation and commercial general liability insurance over an initial two-year term with one-year renewal option. The Texas Health and Human Services Commission, by contrast, issued an RFI to gather vendor capabilities around direct-to-manufacturer prescription fulfillment and therapeutic pharmacy initiatives outside traditional pharmacy benefit manager and group purchasing organization channels, signaling state-level interest in alternative pharmaceutical supply and contracting models.

Activity under this code concentrates in Florida and Texas, with the most recent opportunities posted in mid-2026. The Seminole County IFB (due July 26, 2023, per the solicitation posting) targets community health initiatives and opioid-response supply chains. The Texas HHS RFI (response deadline April 3, 2026) represents a preliminary phase of market intelligence designed to inform future formal procurement specifications and implementation timelines for pharmacy benefit programs serving state employees and retirees. Neither opportunity specifies explicit set-aside designations for disadvantaged enterprises, though the Seminole County procurement references FEMA potential funding with attendant federal compliance requirements including the Clean Air Act and Federal Water Pollution Control Act. The mismatch between the code's nominal pharmaceutical commodity (prednisolone valerate acetate, a topical corticosteroid) and the actual procurement activity (naloxone, drug deactivation systems, and direct pharmaceutical contracting) suggests that state and local agencies are tagging health-supply and pharmacy-services procurements to this code without precision alignment to its specific drug classification.